Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8466137 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
US8466138 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
US8741881 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
US8729057 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
US8754070 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
US8466136 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
US8759329 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
US8486925 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) |
Androgel is owned by Abbvie.
Androgel contains Testosterone.
Androgel has a total of 8 drug patents out of which 0 drug patents have expired.
Androgel was authorised for market use on 29 April, 2011.
Androgel is available in gel, metered;transdermal, gel;transdermal dosage forms.
Androgel can be used as testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
The generics of Androgel are possible to be released after 12 October, 2026.
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 29 April, 2011
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL